ReviewAustralian prescriber2016
Treating osteoporosis.
Review in Australian prescriber, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 33 citations in OpenAlex.
- Sex differences and predictors of anti-osteoporosis medication use in the 12 months after hip fracture surgery in adults 65 or older.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2024Article
- Osteoporosis management-current and future perspectives - A systemic review.Journal of orthopaedics · 2024Review
- Evaluating the Role of Probiotics in the Prevention and Management of Age-Related Diseases.International journal of molecular sciences · 2022Review
- The effects of combined amplitude and high-frequency vibration on physically inactive osteopenic postmenopausal women.Frontiers in physiology · 2022Article
- Zoledronic acid does not slow spinal radiographic progression of osteoarthritis in postmenopausal women with osteoporosis and radiographic osteoarthritis.Therapeutic advances in musculoskeletal disease · 2022Article
- Cumulative Effects of Strontium Ranelate and Impact Exercise on Bone Mass in Ovariectomized Rats.International journal of molecular sciences · 2021Article
- Dual roles of QOA-8a in antiosteoporosis: a combination of bone anabolic and anti-resorptive effects.Acta pharmacologica Sinica · 2018Article
- Article
- Adaptation to microgravity, deconditioning, and countermeasures.The journal of physiological sciences : JPS · 2017Review
- Treating osteoporosis.Australian prescriber · 2016Article
- Treating osteoporosis: concerns about calcium.Australian prescriber · 2016Article
Corrections and comments
- Commented on by
- Commented on by
- Commented on by
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Osteoporotic fractures are common resulting in increased morbidity and mortality. Exercise can help prevent osteoporosis. It can also benefit patients with osteoporosis, but the exercises must be tailored to the patient. Most Australians should be able to obtain adequate calcium in their diet and vitamin D from the sun. Supplements may be needed in some patients and they are recommended for use with other drugs for osteoporosis. Bisphosphonates, and in some patients denosumab, are first-line drugs for osteoporosis. Raloxifene and strontium ranelate can be considered in patients who cannot take bisphosphonates or denosumab. Teriparatide is reserved for patients with severe osteoporosis and the use of strontium ranelate is declining because of cardiovascular safety concerns.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.